

Novartis, ACZ885 – Impressive data in SJIA, but no meaningful commercial opportunity

<https://marketpublishers.com/r/NA78E03DEF3EN.html>

Date: June 2012

Pages: 1

Price: US\$ 90.00 (Single User License)

ID: NA78E03DEF3EN

Abstracts

Novartis today reported positive Phase 3 data on ACZ885 (canakinumab) in SJIA. The data is impressive but commercial opportunity would be limited as SJIA is a rare disease, while NVS may not be able to price the drug accordingly as Actemra which is already approved in this indication costs approximately \$20000 or less depending on the weight. While if NVS chose to price ACZ885 at its existing annual cost (\$100,000), it may not be able to get reasonable market share. We forecast \$30m in incremental sales for ACZ885 in SJIA.

Contents

COMPANIES MENTIONED

Novartis

I would like to order

Product name: Novartis, ACZ885 – Impressive data in SJIA, but no meaningful commercial opportunity

Product link: <https://marketpublishers.com/r/NA78E03DEF3EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA78E03DEF3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970